What assessments and management steps are recommended at a follow‑up visit for a patient who has been on lisdexamfetamine (Vyvanse) for many years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Follow-Up Management for Long-Term Vyvanse (Lisdexamfetamine) Treatment

At follow-up visits for patients on long-term Vyvanse therapy, systematically assess ADHD symptom control, monitor for misuse/diversion, evaluate cardiovascular parameters (blood pressure, heart rate), track growth metrics (height, weight, BMI), screen for common side effects (appetite suppression, insomnia, psychiatric symptoms), and verify medication adherence.

Core Assessment Components

1. Symptom Control and Treatment Response

  • Evaluate target ADHD symptoms using standardized rating scales (e.g., ADHD-RS-IV) from both patient and collateral sources 1
  • Obtain reports from teachers/employers when applicable to assess functional improvement across settings 1
  • For adolescents and adults, include self-ratings of symptom severity 1
  • Assess functional outcomes beyond symptom scores—academic performance, work productivity, driving safety (particularly for adolescents), and interpersonal relationships 2

2. Medication Misuse and Diversion Screening

This is particularly critical given Vyvanse's Schedule II classification despite its lower abuse potential compared to immediate-release amphetamines.

  • Monitor prescription refill patterns for early requests or inconsistent timing 2
  • Screen for diversion behaviors: giving/selling medication to others, requests for dose escalation without clinical justification 2
  • Assess for substance use, especially in adolescents and young adults—this includes alcohol, cannabis, and other stimulants 2
  • Ask directly about methods of administration (patients should be taking medication orally as prescribed) 3

3. Cardiovascular Monitoring

Measure at every visit 3:

  • Blood pressure and pulse rate—expect mean increases of 2-4 mmHg (BP) and 3-6 bpm (pulse) on stimulants 3
  • Document potentially clinically important (PCI) elevations:
    • Pulse rate increases warranting attention occurred in 7% of pediatric patients in long-term studies 4
    • PCI high systolic BP: 22.4% of children, 15.2% of adolescents 4
    • PCI high diastolic BP: 38.8% of children, 21.4% of adolescents 4

Reassess cardiac risk factors periodically, particularly if new symptoms emerge (chest pain, syncope, palpitations) 3

4. Growth Monitoring (Pediatric Patients)

Critical for children and adolescents given CNS stimulants' association with growth suppression 3:

  • Measure height and weight at each visit 1
  • Calculate and plot BMI percentiles 4
  • Expected changes with long-term treatment (based on 2-year data): mean weight gain of only 2.1 kg, height increase of 6.1 cm, and BMI decrease of -0.5 kg/m² 4
  • Watch for shifts to lower z-score categories for height, weight, and BMI—this occurred commonly in long-term studies 4
  • Consider treatment interruption (drug holidays) if growth is not progressing as expected 3

5. Side Effect Assessment

Systematically ask about specific known side effects rather than general inquiries 1:

Most common treatment-emergent adverse events (from long-term studies):

  • Decreased appetite (49.4% in pediatric studies)—typically onset at 13.5 days, duration 169 days 4
  • Insomnia (13-19.5%)—onset at 17 days, duration 42.8 days 4, 5
  • Weight loss (18.2%)—onset at 29 days, duration 225 days 4
  • Headache (5.7-17.2%)—onset at 22 days, brief duration (2 days) 4, 5
  • Irritability (8.6-11.2%) 4, 5
  • Upper respiratory infections (21.8% in adults) 5
  • Dry mouth (16.6% in adults) 5

Psychiatric symptoms requiring specific screening 3:

  • Psychotic symptoms: hallucinations, paranoia, delusional thinking (rare: ~0.1% in pooled studies) 3
  • Mood changes: mania, hypomania, increased aggression 3
  • Suicidal ideation: occurred in 2 of 314 patients in 2-year pediatric study 4
  • Tics: reported in 5.1% of long-term pediatric patients 4

Peripheral vasculopathy (Raynaud's phenomenon): Ask about digital color changes, numbness, or pain in fingers/toes 3

6. Medication Adherence Verification

  • Review dosing schedule: Vyvanse should be taken once daily in the morning 3
  • Confirm proper administration: swallowed whole or mixed with water/yogurt/orange juice (not stored after mixing) 3
  • Assess timing: afternoon doses should be avoided due to insomnia risk 3
  • Identify barriers: cost, forgetfulness, side effects, perceived lack of benefit

7. Dose Optimization

For patients with suboptimal response:

  • Verify adherence first before dose adjustment
  • Maximum recommended dose is 70 mg/day for ADHD 3
  • Dose adjustments in renal impairment: maximum 50 mg/day for severe renal impairment (GFR 15-30), maximum 30 mg/day for ESRD 3
  • Consider drug interactions affecting amphetamine levels (urinary pH modifiers) 3

Visit Frequency

Maintenance phase monitoring (after initial titration):

  • Monthly visits initially until symptoms are stabilized 1
  • Frequency should increase if there are concerning side effects, comorbid psychiatric conditions, adherence problems, or signs of misuse 1
  • Long-term stable patients may transition to less frequent monitoring, but never eliminate systematic assessment of the core parameters above

Common Pitfalls to Avoid

  1. Failing to obtain collateral information: Relying solely on patient self-report misses important functional outcomes, particularly in children and adolescents 1

  2. Neglecting growth monitoring in pediatric patients: This is a black box concern requiring systematic tracking 3

  3. Missing early signs of misuse: Adolescents are at highest risk for diversion; monitor refill patterns and screen for substance use 2

  4. Inadequate cardiovascular monitoring: Small mean increases can mask clinically significant elevations in individual patients 3, 4

  5. Dismissing psychiatric symptoms as "just ADHD": New-onset psychosis, mania, or suicidality requires immediate evaluation and potential medication discontinuation 3

  6. Continuing ineffective treatment: If symptoms remain poorly controlled despite adequate dosing and adherence, consider switching medications or adding behavioral interventions rather than exceeding maximum doses 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.